logo
logo

Vizgen Secures $37M Series B Financing To Advance Spatial Genomics Through Commercialization Of Merscope™ Platform

Apr 07, 2021over 4 years ago

Amount Raised

$37 Million

Round Type

series b

Cambridge

Description

Vizgen, the life science company dedicated to advancing human health by visualizing single-cell spatial genomics information, has closed a $37 million Series B financing. The financing was co-led by Novalis LifeSciences LLC, and current investor Northpond Ventures. Also participating in the round were new investors Tao Capital Partners, Pura Vida Investments, LLC, and a large U.S. endowment fund

Company Information

Company

Vizgen

Location

Cambridge, Maryland, United States

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech